Connect your AI

Delcath Systems DCTH Proceeds from disposition of marketable securities and other investments

Proceeds from disposition of marketable securities and other investments at other companies

Viking TherapeuticsVKTX

——

Jazz PharmaceuticalsJAZZ

——

Other financials

Income statement

Revenue$25.0M+26.3%

Gross profit$21.3M+25.5%

Operating income-$1.6M-355%

Net income-$1.1M-200%

EPS (diluted)-$0.03-200%

Balance sheet

Cash & equivalents$41.3M+223%

Total debt$907.0K-10.7%

Total equity$112.7M+40.5%

Total assets$124.8M+43.0%

Cash flow

Operating cash flow$857.0K-61.1%

CapEx$570.0K+307%

Free cash flow$287.0K-86.1%

Valuation

Market cap$425.31M-11.8%

Enterprise value$384.91M-18.2%

P/E120.6×—

P/S4.7×-4.3×

Profitability

Gross margin86%+1.1pp

Operating margin-118.1%-56.8pp

Net margin1.5%+0.8pp

FCF margin21.2%+15.2pp

Returns & leverage

Return on equity1.9%+1.0pp

Debt / equity0×0.0×

Current ratio11.2×-4.7×

Where this comes from

Reported directly by Delcath Systems in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments.

The official record: Delcath Systems’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Delcath Systems's proceeds from disposition of marketable securities and other investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Delcath Systems's proceeds from disposition of marketable securities and other investments?: Delcath Systems (DCTH) reported proceeds from disposition of marketable securities and other investments of $15.81M in Q1 2026.
How has Delcath Systems's proceeds from disposition of marketable securities and other investments changed year-over-year?: Delcath Systems's proceeds from disposition of marketable securities and other investments increased by 213.0% year-over-year, from $5.05M to $15.81M.